Perrigo Shareholder Lawsuits Claim Joining Mylan Was A Better Idea
This article was originally published in The Pink Sheet
Executive Summary
Two complaints seeking compensation for Perrigo shareholders and four motions seeking lead plaintiff designations in the litigation have been filed in US district court. Both target Perrigo's fundamental argument against Mylan's takeover bid in 2015, that the company would be stronger continuing on its own.
You may also be interested in...
OTC Private Label Anchors Perrigo Amid Branded Business Turmoil
CEO John Hendrickson and CFO Judy Brown reassure investors that Perrigo's US OTC private label platform supports the firm as it makes changes to turn around its European branded product business that stumbled soon after being put together.
Culture Shock In Europe For Perrigo With Branded Consumer Business
Less than a month after moving up from president to CEO, John Hendrickson tells analysts during the firm's first-quarter earnings briefing that Perrigo's private label OTC drug business remains strong, with the next launch ready to ship, but growing European branded consumer product sales is more of a long-term goal.
Perrigo Navigates Earnings Storm Weathering Change At Helm
The OTC private label giant promotes John Hendrickson from president to CEO after Joseph Papa resigns to take the same post at beleaguered specialty pharma Valeant Pharmaceutical International. A lower earnings forecast combined with the leadership change sent Perrigo's share price down 18.09%.